Apogee Therapeutics (NASDAQ:APGE) Price Target Raised to $128.00

Apogee Therapeutics (NASDAQ:APGE) had its price target hoisted by BTIG Research from $115.00 to $128.00 in a research note released on Monday, Marketbeat.com reports. The firm currently has a buy rating on the stock.

A number of other analysts have also weighed in on APGE. Weiss Ratings reissued a “sell (d-)” rating on shares of Apogee Therapeutics in a research report on Wednesday, October 8th. Deutsche Bank Aktiengesellschaft assumed coverage on Apogee Therapeutics in a research note on Tuesday, December 9th. They set a “buy” rating and a $103.00 target price on the stock. Mizuho initiated coverage on Apogee Therapeutics in a research note on Tuesday, October 21st. They set an “outperform” rating and a $105.00 price target for the company. Craig Hallum began coverage on Apogee Therapeutics in a report on Monday, November 3rd. They set a “buy” rating and a $109.00 price objective for the company. Finally, Royal Bank Of Canada upped their price objective on Apogee Therapeutics from $60.00 to $70.00 and gave the company an “outperform” rating in a research report on Monday, November 3rd. Two analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Apogee Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $104.27.

Apogee Therapeutics Stock Up 0.9%

NASDAQ APGE opened at $78.95 on Monday. The company has a fifty day moving average of $70.03 and a two-hundred day moving average of $51.41. The firm has a market capitalization of $5.39 billion, a price-to-earnings ratio of -18.03 and a beta of 1.41. Apogee Therapeutics has a 52 week low of $26.20 and a 52 week high of $80.99.

Apogee Therapeutics (NASDAQ:APGE) last announced its earnings results on Monday, November 10th. The company reported ($1.11) earnings per share for the quarter, beating the consensus estimate of ($1.14) by $0.03. Equities research analysts anticipate that Apogee Therapeutics will post -3.09 EPS for the current year.

Insider Buying and Selling

In related news, insider Carl Dambkowski sold 10,900 shares of the stock in a transaction that occurred on Thursday, December 4th. The stock was sold at an average price of $75.00, for a total value of $817,500.00. Following the transaction, the insider owned 271,108 shares of the company’s stock, valued at $20,333,100. This represents a 3.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Michael Thomas Henderson sold 20,000 shares of the firm’s stock in a transaction on Wednesday, December 10th. The stock was sold at an average price of $75.38, for a total value of $1,507,600.00. Following the transaction, the chief executive officer owned 1,212,987 shares in the company, valued at $91,434,960.06. The trade was a 1.62% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 101,685 shares of company stock valued at $7,179,630 in the last quarter. 42.77% of the stock is owned by company insiders.

Hedge Funds Weigh In On Apogee Therapeutics

Institutional investors have recently made changes to their positions in the company. JPMorgan Chase & Co. raised its holdings in shares of Apogee Therapeutics by 57.9% in the third quarter. JPMorgan Chase & Co. now owns 1,137,731 shares of the company’s stock valued at $45,202,000 after acquiring an additional 417,161 shares in the last quarter. Verition Fund Management LLC purchased a new position in Apogee Therapeutics during the 3rd quarter valued at about $1,968,000. Vestal Point Capital LP bought a new stake in shares of Apogee Therapeutics in the 3rd quarter valued at about $16,885,000. Polar Capital Holdings Plc raised its holdings in shares of Apogee Therapeutics by 5.9% in the 3rd quarter. Polar Capital Holdings Plc now owns 524,094 shares of the company’s stock valued at $20,822,000 after purchasing an additional 29,094 shares in the last quarter. Finally, Prelude Capital Management LLC purchased a new stake in shares of Apogee Therapeutics in the 3rd quarter worth approximately $1,043,000. Hedge funds and other institutional investors own 79.04% of the company’s stock.

Key Headlines Impacting Apogee Therapeutics

Here are the key news stories impacting Apogee Therapeutics this week:

• Positive Sentiment: Positive Phase 1b interim results: Zumilokibart showed rapid, durable suppression of FeNO (a Type‑2 inflammation biomarker) through 16 weeks and up to 32 weeks in follow‑up patients, supporting less‑frequent (3‑ or 6‑month) dosing and continued development in asthma. Apogee Therapeutics Announces Positive Interim Results from Phase 1b Trial of Zumilokibart
• Positive Sentiment: Stifel raised its price target to $133 (from $95), signaling stronger sell‑side confidence after the data and likely contributing to buy‑side interest. Apogee Therapeutics price target raised to $133 from $95 at Stifel
• Positive Sentiment: BTIG boosted its price target to $128, another analyst upgrade that lifts forward valuation expectations for APGE. BTIG Research Boosts Apogee Therapeutics (NASDAQ:APGE) Price Target to $128.00
• Positive Sentiment: Citi issued a Buy on APGE, adding to the broker support following the data release and analyst re‑ratings. Apogee Therapeutics (APGE) Receives a Buy from Citi
• Neutral Sentiment: Company hosted / announced a conference call to discuss the interim Phase 1b results and 2026 milestones — useful for investors wanting management color, timeline and next steps. Apogee Therapeutics to Host Conference Call to Report Interim Results
• Neutral Sentiment: Full transcript and coverage of the interim results provide greater detail on safety, biomarker response and development plans — useful for modeling but not an immediate price driver beyond the topline. Apogee Therapeutics Discusses Interim Phase Ib Results of Zumilokibart (Transcript)
• Negative Sentiment: Insider sale: CMO Carl Dambkowski sold 10,900 shares for ~$817,500 on Dec. 4 (about 3.87% of his direct holdings), which can raise short‑term investor concerns about insider liquidity or timing. Apogee Therapeutics Chief Medical Officer Sells $817,500 Worth of Shares
• Negative Sentiment: Some outlets reported an initial stock decline after the asthma data, indicating mixed/volatile market reactions and possible profit‑taking despite positive biomarkers. Monitor volume and follow‑through. Apogee Therapeutics stock falls after asthma trial data

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc is a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics that selectively target the nuclear receptor RORγt, a master regulator of T cell-driven inflammatory pathways. By modulating RORγt activity, Apogee aims to offer an oral treatment option for patients with autoimmune and inflammatory skin disorders.

The company’s lead candidate, APG-157, is an oral RORγt inverse agonist currently undergoing early-stage clinical evaluation for moderate to severe plaque psoriasis.